MYBL1 and adrenocortical carcinoma, hereditary: AdCC is a rare, insidious, and highly recurrent head and neck malignancy, with no effective systemic therapy yet identified.[1] The carcinogenic mechanism of AdCC has been gradually elucidated, mainly involving the translocation of MYB family genes.[3] Although clinical study reveal no significant difference in overall survival (OS) between AdCC patients with or without MYB or MYBL1 fusion,[3] genomic analysis helps to explore the connection between pathways and target genes in AdCC diagnosis and potential treatments.